Loading...
•
Dec 31, 2020
scPharmaceuticals Q4 2020 Earnings Report
Reported financial results for the fourth quarter and full year ended December 31, 2020, and provided a business update.
Key Takeaways
scPharmaceuticals reported a net loss of $7.8 million for the fourth quarter of 2020, and ended the quarter with $105.3 million in cash, cash equivalents, restricted cash and investments. The company believes its cash is sufficient to fund operations through potential FUROSCIX approval and launch into 2023.
Completed Type A meeting with the FDA regarding FUROSCIX NDA resubmission anticipated in Q3 2021.
FDA is not requiring device modifications or additional clinical studies of FUROSCIX.
FREEDOM clinical study on track for topline results in Q3 2021.
Ended Q4 with cash, cash equivalents, restricted cash and investments of $105.3 million, sufficient to fund operations into 2023.
Forward Guidance
Based on its current operating plan, the Company forecasts its 2021 net loss to be $32 to $36 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...